Few comments from Platypus AM from their latest monthly report for March
"Turnover was a touch over 11% in March as we initiated new positions in Acrux and IOOF Holdings, and bought back Myer and ALS Ltd. Acrux has licensed their testosterone product to Eli Lily, which is once again starting to take market share from incumbent treatments."
http://www.platypusassetmanagement.com.au/performance/performance.html
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
-0.001(5.56%) |
Mkt cap ! $6.931M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.9¢ | 1.7¢ | $8.809K | 495.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 266679 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 252359 | 2 |
View Market Depth
| Last trade - 14.49pm 24/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |